The anxiolytics CI-988 and chlordiazepoxide fail to reduce immediate early gene mRNA stimulation following exposure to the rat elevated X-maze

European Journal of Pharmacology

Volumn 312, Issue 2, 1996, Pages 153-161

  Hinks, Gillian L ^a   Brown, Pierre ^a   Field, Mark ^a   Poat, Judith A ^a   Hughes, John ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Anxiety; Benzodiazepine; CCK (cholecystokinin); CI 988; Elevated X maze; Immediate early gene

Indexed keywords

4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; CHLORDIAZEPOXIDE; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; MESSENGER RNA; TRANSCRIPTION FACTOR;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BRAIN; CONTROLLED STUDY; FEAR; GENE EXPRESSION; GENE INDUCTION; IMMEDIATE EARLY GENE; IN SITU HYBRIDIZATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; METHODOLOGY; NONHUMAN; NORTHERN BLOTTING; ONCOGENE C FOS; PRIORITY JOURNAL; RAT;

EID: 0030603210     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(96)00471-2     Document Type: Article

References (39)

1. Angel P., E.A. Allegrtto, S.T. Okino, K. Hattori, W.J. Boyle. T. Hunter and M. Karin, 1988, Oncogene jun encodes a sequence-specific trans-activator similar to AP-1, Nature 332, 166.
2. Bartanusz V., J.-M. Aubrey, D. Jezova, J. Baffi and J.Z. Kiss, 1993, Up-regulation of vasopressin mRNA in paraventricular hypophysiotrophic neurons after acute immobilization stress, Neuroendocrinology 58, 625.
3. Beck C.H.M. and H.C. Fibiger, 1995, Conditioned fear-induced changes in behaviour and in the expression of the immediate early gene c-fos: with and without diazepam pretreatment, J. Neurosci. 15, 709.
4. Bradwejn J., D. Koszychi, A. Couëtoux du Terte, M. Bourin, R. Palmour and F. Ervin, 1992, The cholecystokinin hypothesis of panic and anxiety disorders: a review, J. Psychopharmcol. 6, 345.
5. Bradwejn J., M. Paradis, D. Koszychi, P. Reece and A. Sedman, 1994, The effects of CI-988 on CCK-4-induced panic in healthy volunteers, Can. J. Physiol. Pharmacol. 72, Suppl. 1, 417.
6. Carrive P., 1993, The periaqueductal gray and defensive behavior: functional representation and neuronal organisation, Behav. Brain Res. 58, 27.
7. Costall B., A.M. Domeney, J. Hughes, M.E. Kelly, R.J. Naylor and G.N. Woodruff, 1991, Anxiolytic effects of CCK-B antagonists, Neuropeptides 19 (Suppl.), 65.
8. Cullinan W.E., J.P. Herman, D.F. Battaglia, H. Akil and S.J. Watson, 1995, Pattern and time course of immediate early gene expression in rat brain following acute stress, Neuroscience 64, 477.
9. Curran T. and N.M. Teich, 1982, Candidate product of the FBJ murine osteosarcoma virus oncogene: Characterization of a 55,000 dalton phosphoprotein, J. Virol. 42, 114.
10. Curran T., M.B. Gordon, K.L. Ribino and L.C. Sambucetti., 1987, Isolation and characterization of the c-fos (rat) cDNA and analysis of post-translational modification in vitro, Oncogene 2, 79.
11. Davis M., 1992, The role of the amygdala in fear and anxiety, Annu. Rev. Neurosci. 15, 353.
12. A receptor mechanism, Neuropharmacology 33, 719.
13. Diorio D., V. Viau and M.J. Meaney, 1993, The role of the medial prefrontal cortex (cingulate gyrus) in the regulation of hypothalamic-pituitary-adrenal responses to stress, J. Neurosci. 13, 3839.
14. Field M.J., A.S. Lewis, C. Lloyd and L. Singh, 1991, Automation of the elevated X-maze test of anxiety, Br. J. Pharmacology 102, 304P.
15. File S.E., 1990, Interactions of anxiolytic and antidepressant drugs with hormones of the hypothalamic-pituitary-adrenal axis, Pharmacol. Ther. 46, 357.
16. Graeff F.G., M.C.L. Silveira, R.L. Nogueira, E.A. Audi and R.M.W. Oliveira, 1993, Role of the amygdala and periaqueductal gray in anxiety and panic, Behav. Brain Res. 58, 123.
17. Gray J.A., 1990, Brain systems that mediate both emotion and cognition, Cognition Emotion 4, 269.
18. Handa R.J., K.M. Nunley and M.R. Bollnow, 1993, Induction of c-fos mRNA in the brain and anterior pituitary gland by a novel environment, Neuroreport 4, 1079.
19. Handley S.L. and S. Mithani, 1984, Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour, Naunyn-Schmiedeberg's Arch. Pharmacol. 327, 1.
20. Harbuz M.S., D.S. Jessop, S.L. Lightman and H.S. Chowdrey, 1994, The effects of restraint or hypertonic saline stress on corticotrophin-releasing factor, arginine vasopressin, and proenkephalin A mRNA in the CFY, Sprague-Dawley and Wistar strains of rat, Brain Res. 667, 6.
21. B receptor subtypes and associated neuropeptide expression in response to salt stress in the rat and mouse, Neuroscience 68, 765.
22. Hughes J., P. Boden, A. Domeney, E. Kelly, D.C. Horwell, J.C. Hunter, R.D. Pinnock and G.N. Woodruff, 1990, Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity, Proc. Natl. Acad. Sci. USA 87, 6728.
23. Iglesias T., S. Montera, M.J. Otero L. Parra L. and J.A. Fuentes, 1992, Preproenkephalin RNA increases in the hypothalamus of rats stressed by social deprivation, Cell. Mol. Neurobiol. 12, 547.
24. Kinney W. and A. Routtenberg, 1993, Brief exposure to a novel environment enhances binding of hippocampal transcription factors to their DNA recognition elements, Mol. Brain Res. 20, 147.
25. Milbrandt J., 1987, A nerve growth-induced gene encodes a possible transcriptional regulatory factor, Science 238, 797.
26. Milbrandt J., 1988, Nerve growth factor induces a gene homologous to the glucocorticoid receptor gene, Neuron 1, 183.
27. Morgan J.I., D.R. Cohen, J.L. Hempstead and T. Curran, 1987, Mapping patterns of c-fos expression in the central nervous system after seizure, Science 237, 192.
28. Onodera H., K. Kogure, Y. Ono, K. Igarashi, Y. Kiyota and A. Hagaoka, 1989, Proto-oncogene c-fos is transiently induced in the cerebral cortex after forebrain ischemia, Neurosci. Lett. 98, 101.
29. Palmour R.M., F.R. Ervin, J. Bradwejn and J. Howbert, 1991, Anxiogenic and cardiovascular effects of CCK in monkeys are blocked by the CCK-B antagonist LY262691, Soc. Neurosci. Abs, 17, 637.1.
30. Paxinos G. and C. Watson, 1986, The Rat Brain in Stereotaxic Coordinates (Academic Press) (2nd edn.).
31. Pellow, S., P. Chopin, S.E. File and M. Briley, 1985, Validation of open:closed arm entries in the elevated Plus-maze as a measure of anxiety in the rat, J. Neurosci. Meth. 14, 149.
32. Phelps M.E., J.C. Mazziotta and S.-C. Huang, 1982. Study of cerebral function with positron computed tomography, J. Cereb. Blood Flow Metab. 2, 113.
33. Powell K.R. and J.E. Barrett, 1991, Evaluation of the effects of PD 134308 (CI-988), a CCK-B antagonist, on punished responding of squirrel monkeys, Neuropeptides 19, 75.
34. Ryder K., L.F. Lau and D. Nathans, 1988, A gene activated by growth factors is related to the oncogene v-jun, Proc. Natl. Acad. Sci. USA 85, 1487.
35. Sambrooke J., E. Frisch and T. Maniatis, 1989, Molecular Cloning: A Laboratory Manual (Cold Spring Harbour Laboratory Press).
36. B receptor antagonist, Br. J. Pharmacol. 104, 239.
37. Singh L., A.S. Lewis, M.J. Field, J. Hughes and G.N. Woodruff, 1991b, Evidence for an involvement of the brain cholecystokinin B receptor in anxiety, Proc. Natl. Acad. Sci. USA 88, 1130.
38. Sokoloff L., 1984, Modelling metabolic processes in the brain in vivo, Ann. Neurol. 15 (Suppl.), S1.
39. Watanabe Y., E. Stone and B.S. McEwen, 1994, Induction and habituation of c-fos and zif/268 by acute and repeated stressors, Neuroreport 5, 1321.